Background The development of immune checkpoint inhibitors (ICIs) represents a paradigm
shift in the treatment of cancers. Despite showing remarkable efficacy, these agents can be …

Myasthenia gravis (MG) is an autoimmune neuromuscular disorder which is characterized
by presence of antibodies against acetylcholine receptors (AChRs) or other proteins of the …

Immune checkpoint inhibitor (ICI)-related myositis is a rare, potentially fatal condition that
warrants further studies. Its incidence, clinical features, and prognosis remain poorly …

Myocarditis associated with the use of immune checkpoint inhibitors (ICI) is a rare
manifestation of their cardiotoxicity, but is characterized by a high mortality rate. A literature …

Immune checkpoint inhibitors (ICIs) and BRAF and MEK inhibitors (BRAFi/MEKi) have
drastically improved the outcome of melanoma patients. ICIs can induce myocarditis, a rare …

With anti-PD-1 antibodies serving as a representative drug, immune checkpoint inhibitors
(ICIs) have become the main drugs used to treat many advanced malignant tumors …

Immune checkpoint therapies (ICT) can induce life-threatening immune-related adverse
events, including myocarditis and myositis, which are rare but often concurrent. The …

Introduction Immune therapy has ushered in a new era of tumor treatment, at the expense of
immune-related adverse events, including rare but fatal adverse cardiovascular events, such …

The use of immunotherapies like pembrolizumab (PEM) is increasingly common for the
management of numerous cancer types. The use of PEM to bolster T-cell response against …

Background Immune checkpoint inhibitors can result in overlap syndrome comprised of
myasthenia gravis, myositis and myocarditis. However, the mortality predictors have not …